Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Astonea LabsBOM:544409 +1.01%12 EBITDA Margin % is 10.34% as of Mar. 2026, which is 30% below its 10-year median of 14.85. GuruFocus rates BOM:544409 with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 960 Drug Manufacturers companies, Astonea Labs ranks worse than 55.63% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Astonea Labs's EBITDA for the
three
months ended in Mar. 2026 was ₹84.1 Mil. Astonea Labs's Revenue for the
three
months ended in Mar. 2026 was ₹812.9 Mil. Therefore, Astonea Labs's EBITDA margin for the quarter that ended in Mar. 2026 was 10.34%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Astonea Labs EBITDA Margin % Related Terms
Astonea Labs EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Astonea Labs's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Astonea Labs's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astonea Labs EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astonea Labs's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Astonea Labs's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astonea Labs (BOM:544409) has a EBITDA Margin % of 10.34% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Astonea Labs and its competitors. This is 30% below median its historical median of 14.85. Over the past decade, Astonea Labs' EBITDA Margin % has ranged from 9.45 to 20.05. According to the industry distribution chart, Astonea Labs ranks #534 out of 960 companies in the Drug Manufacturers industry, placing it in the top 55.6%.
Is Astonea Labs' EBITDA Margin % too high?
Astonea Labs' current EBITDA Margin % of 10.34% is 30% below median its 10-year median of 14.85. Over the past 10 years, this metric has ranged from a low of 9.45 to a high of 20.05. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Astonea Labs' value of 10.34% is 17.4% below this industry median. Based on the distribution chart, Astonea Labs ranks #534 out of 960 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Astonea Labs has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Astonea Labs' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Astonea Labs ranks #534 out of 960 companies for EBITDA Margin %. This places Astonea Labs in the lower half of its industry. The industry median EBITDA Margin % is 12.52. Astonea Labs' value of 10.34% is 17.4% below this benchmark. Historically, Astonea Labs' own EBITDA Margin % has ranged from 9.45 to 20.05 over the past decade. While the company's 10-year median is 14.85 vs. the industry median of 12.52, Astonea Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astonea Labs's current EBITDA Margin % of 10.34% is 17.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Astonea Labs and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astonea Labs's current EBITDA Margin % is 10.34%, which is 30% below median its own 10-year median of 14.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astonea Labs stock overvalued right now?
Astonea Labs (BOM:544409) has a current EBITDA Margin % of 10.34%. The current EBITDA Margin % is 10.34%, which is 30% below median its 10-year median of 14.85 and 17.4% below the Drug Manufacturers industry median of 12.52. Astonea Labs' overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Astonea Labs (BOM:544409), the current EBITDA Margin % is 10.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Astonea Labs Ltd is an India-based pharmaceutical and cosmetics company engaged in the manufacturing and development of healthcare and personal care products. The Company operates in the pharmaceuticals and cosmetics & personal care space, offering products that include generic medicines, OTC products, specialty therapeutics, nutraceuticals, and biosimilars, as well as skincare, haircare, anti-aging, ethical, and organic cosmetic products, supported by in-house research and development and contract manufacturing services. Its business activities are organized across key segments comprising Pharmaceuticals, Cosmetics & Personal Care, R&D & Innovation, and Contract Manufacturing (CDMO).
12GF Score
Get the complete analysis for BOM:544409
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544409 has been successfully added to your 
